Abstract
Cancer diseases are the second leading cause of death in the Czech Republic. The incidence of primary malignant brain tumours is approximately 8/100,000 and metastatic CNS involvement is nine times higher.
This article deals with new real options and perspectives of their treatment resulting from the application of oncogenesis research. It presents some classic biomarkers that have substantially changed the classification of gliomas - the largest group of primary brain tumours.
Examples of essential studies are given which have changed the approach to glioma treatment. References are made to the latest EANO guidelines on the treatment of diffuse gliomas.
Briefly discussed are the nature and new options of personalized immunological treatment of primary tumours as well as metastases. A model approach to the diagnosis and treatment of lymphomas is presented.
Information on adverse effects of immunological cancer treatment is also provided.